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Abstract
Background: Porcine contagious pleuropneumonia (PCP) is a highly contagious disease that is caused by
Actinobacillus pleuropneumoniae (APP) and characterized by severe fibrinous necrotizing hemorrhagic
pleuropneumonia, which is a severe threat to the swine industry. In addition to APP RTX-toxins I (ApxI), APP RTX-
toxin II (ApxII), APP RTX-toxin III (ApxIII) and Outer membrane protein (OMP), there may be other useful antigens
that can contribute to protection. In the development of an efficacious vaccine against APP, the immunogenicities
of multicomponent recombinant subunit vaccines were evaluated.
Methods: Six major virulent factor genes of APP, i.e., apxI, apxII, apxIII, APP RTX-toxins IV (apxIV), omp and type 4
fimbrial structural (apfa) were expressed. BALB/c mice were immunized with recombinant ApxI ( rApxI),
recombinant ApxII (rApxII), recombinant ApxIII (rApxIII) and recombinant OMP (rOMP) (Group I); rApxI, rApxII, rApxIII,
recombinant ApxIV (rApxIV), recombinant Apfa (rApfa) and rOMP (Group II); APP serotype 1 (APP1) inactivated
vaccine (Group III); or phosphate-buffered saline (PBS) (Control group), respectively. After the first immunization,
mice were subjected to two booster immunizations at 2-week intervals, followed by challenge with APP1 Shope
4074 and APP2 S1536.
Results: The efficacy of the multicomponent recombinant subunit vaccines was evaluated on the basis of antibody
titers, survival rates, lung lesions and indirect immunofluorescence (IIF) detection of APP. The antibody level of
Group I was significantly higher than those of the other three groups (P < 0.05). The survival rate of Group I was
higher than that of Groups II and III (P < 0.05) and the control (P < 0.01). Compared with the other three groups,
the lungs of Group I did not exhibit obvious hemorrhage or necrosis, and only showed weak and scattered
fluorescent dots by IIF detection.
Conclusion: The result indicates that the multicomponent recombinant subunit vaccine composed of rApxI, rApxII,
rApxIII and rOMP can provide effective cross-protection against homologous and heterologous APP challenge.
Background
Porcine contagious pleuropneumonia (PCP) is a highly
contagious disease that is caused by Actinobacillus
pleuropneumoniae (APP) and characterized by severe
fibrinous necrotizing hemorrhagic pleuropneumonia [1],
which is a severe threat to the swine industry.
At present, an inactivated whole cell vaccine derived
from APP is used for PCP prevention in many countries
[2,3]. However, the protection provided by the inacti-
vated vaccine is not sufficient [4,5], for the reason that
the inactivated vaccine rarely contains exotoxins
excreted to the medium by the bacteria during growth
[6-8]. In addition, some protein components may be
damaged or lost during the inactivation process. Several
studies have shown that effective protection can be pro-
vided by combined subunit vaccines composed of viru-
lence factors of APP [9,10], such as transferrin-binding
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any medium, provided the original work is properly cited.protein, lipoprotein [11], capsular polysaccharide [CPS]
or lipopolysaccharide [LPS] [12]. Combined subunit vac-
cines, such as the multicomponent vaccine composed of
APP RTX-toxins I (ApxI), APP RTX-toxin II (ApxII),
APP RTX-toxin III (ApxIII) and Outer membrane pro-
tein (OMP), can provide higher protective efficacy
against challenge with 12 serotypes of APP [13,14],
which demonstrates that the development of multicom-
ponent subunit vaccines should be pursued further.
In addition to ApxI, ApxII, ApxIII and OMP, there may
be other useful antigens that can contribute to protection.
As an important virulent factor, the pilus has excellent
immunogenicity among many Gram-negative bacteria
[15-17]. The enterotoxigenic CS4 pilus of Escherichia coli
(E. coli) [18] and the toxin-coregulated pilus (TCP) of
Vibrio cholerae [19] have been chosen as candidate anti-
gens for subunit vaccines. The type 4 fimbrial structural
gene (apfA) of APP was shown to be present and highly
preserved in different serotypes of APP [20,21], which sug-
gests that the pilus of APP may have potential to be a
component for vaccine preparation.
APP RTX-toxin IV (ApxIV) toxin is another poten-
tially valuable antigen that has been identified within
recent years as an APP toxin. The ApxIV toxin was
shown to be the only toxin that can be produced by all
s e r o t y p e so fA P Pa n di so n l ye x p r e s s e di nv i v od u r i n g
infection. Moreover, ApxIV toxin can stimulate a high
level of antibody [22]. These findings indicate that
A p x I Vt o x i nm a yb er e s p o n s i b l ef o rc r o s s - p r o t e c t i o ni n
pigs that have recovered from natural infection and are
resistant to reinfection with any other serotype of APP.
In this study, we cloned and expressed ApxI, ApxII,
ApxIII toxins, OMP as well as the Apfa and ApxIV
t o x i no fA P P .O nt h eb a s i so ft h e s er e c o m b i n a n ta n t i -
gens, different multi-component recombinant vaccines
were made, and the efficacy of these vaccines was evalu-
ated in order to determine whether the Apfa toxin can
contribute to the protective immunity of a recombinant
subunit vaccine.
Materials and methods
Bacterial strains, growth conditions, vectors and sera
The APP serotype 1 reference strain Shope 4074, APP
serotype 2 reference strain S1536 and E. coli BL21 were
obtained from the Chinese Institute of Veterinary Drug
Control (IVDC); the prokaryotic expression vector
pGEX-6P-1 was purchased from Invitrogen (Carlsbad,
CA, USA). Rabbit antisera were produced by immuniza-
tion of rabbits with inactivated APP1 and APP2; the
immunization was performed by multipoint subcuta-
neous injections, and the immunization schedule com-
prised three immunizations at 2-week intervals. Ten
days after the third immunization, blood was collected
and the serum was separated and stored in our
laboratory. The APP was grown in beef heart infusion
broth or agar supplemented with 10% horse serum and
100 μg/ml Nicotinamide Adenine Dinucleotide (NAD),
and the E. coli BL21 strain was grown in Luria-Bertani
(LB) broth or agar containing 50 μg/ml ampicillin.
Mice
Male BALB/c mice (n = 80), aged 6 weeks, were pur-
chased from Harbin Medical University. Animal experi-
ments were performed in accordance with the
guidelines of Chinese Council on Animal Care. The
research protocol was approved by Harbin Veterinary
Research Institute Committees on Biosafety.
Expression and purification of recombinant proteins
The genes apxIA, apxIVA, apfa and omp were amplified
from the APP1 Shope 4074 genome; apxIIA and apxIIIA
were amplified from the APP2 S1536 genome by PCR
according to the reaction conditions shown in Table 1.
The amplified fragments were cloned into pGEX-6P-1,
resulting in the recombinant plasmids pGEX-apxIA,
pGEX-apxIIA, pGEX-apxIIIA, pGEX-apxIVA, pGEX-
apfa and pGEX-omp (for the restriction enzymes used
for cloning, see Table 1). The recombinant plasmids
were transformed into E. coli BL21 and expressed by
induction with 1 mmol/L isopropyl-b-D-thiogalactoside
(IPTG) under cultivation at 37°C for 4-6 h. All of the
expressed recombinant proteins formed inclusions
except for rOMP. The inclusion proteins were purified
after denaturation and renaturation. The process
involved two to three washes with 50 mmol/L Tris-HCl
(pH 8.0), 1 mmol/L Ethylene Diamine Tetraacetic Acid
(EDTA) containing 0.5% Triton X-100, dissolution in 6
mol/L guanidine hydrochloride, dilution, dialysis against
20 mmol/L Tris-HCl (pH 8.3), 1 mmol/L EDTA, and
concentration by Polyethylene Glycol (PEG) 20 000.
This was followed by redialysis against 20 mmol/L Tris-
HCl (pH 8.3) and 1 mmol/L EDTA. The soluble ApxI,
rApxII, rApxIII, rApxIV and rApfa as well as rOMP
were purified using a MicroSpin GST Purification Mod-
ule (Amersham Pharmacia Biotech Co., Piscataway, NJ,
USA) according to the manufacturer’s instructions. The
concentration of the recombinant proteins was deter-
mined using the Bradford method as described pre-
viously [23].
Western blotting
Western blot analysis of recombinant proteins after
sodium dodecyl sulfate polyacrylamide gel electrophor-
esis (SDS-PAGE) was performed as described pre-
viously [23]. Rabbit antisera against APP1 (for rOMP,
rApxI, rApxIV and rApfa) or APP2 (for rApxII and
rApxIII) were used at a 1:50 dilution as the first anti-
body and horse radish peroxidase (HRP)-conjugated
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Aldrich, St. Louis, MO, USA) at 1:5 000 dilution as the
second antibody. 3, 3’-Diaminobenzidine (DAB) was
used as the staining substrate.
Immunization of mice
Male BALB/c mice (n = 80) were randomly allocated in
equal numbers to each of three vaccination treatments
and a PBS control, twenty mice were used in each
group. The mice were immunized using 0.2 ml for each
group [7] (Table 2). The immunization was performed
by multipoint subcutaneous injection. The first, second
and third immunizations were performed at 7, 9 and 11
weeks of age, respectively. One week after the first
immunization, blood was harvested each week from the
tail vein (0.1 ml/animal) for the serum antibody assay.
Antibody analysis
Specific antibodies were measured by indirect ELISA
(iELISA) [24]. Native ApxI, ApxII, ApxIII, Apfa and
OMP were extracted as described previously [25-27].
Because ApxIV is expressed only in vivo during
infection, it could not been extracted from the culture
of APP. The crude extracts were recovered and purified
by 12% SDS-PAGE. The ELISA plates (Costar,
eBioscience, San Diego, CA, USA) were coated with 10
μg/ml ApxI, ApxII, ApxIII, Apfa or OMP (50 μl/well).
Sera of immunized mice were diluted (1:100, 50 μl/well)
with PBST (PBS with 0.1% Tween 20) as the first anti-
body, and HRP-conjugated goat anti-mouse IgG (Sigma
Aldrich) (1:10 000 dilution, 50 μl/well) was used as the
second antibody. Washing was carried out three times
with PBST between each step. All reaction mixtures
were set up in triplicate, and the average values were
used for recording and calculation. The results were
read on a Dynatech MR 7000 ELISA reader (Bio-Rad
mode l680). The OD490 was read to record the ELISA
score.
Data analysis
The data were analyzed using the general linear model
(GLM) procedure of Statistical Analysis System (SAS,
1997. Base SAS Software Reference Card. Version 6.12,
Cary, NC, SAS Institute Inc., USA, p.211-253).
Table 1 Primers, sequences and PCR conditions used for the amplification of apxIA, apxIIA, apxIIIA, apxIVA, omp and
apfa from Actinobacillus pleuropneumoniae
Genes Primer sequences (5’-3’) Annealing
temperature
Size of PCR
product (bp)
apxIA Forward: GCGGGATCCAACTCTCAGCTCGATAG 55°C 2520
Reverse: GATGCGTCGACAGCAGATTGTGTTAAAT
apxIIA Forward: GCGGGATCCATGTCAAAAATCACTT 54°C 2721
Reverse: GCGAATTCAGCGGCTCTAGCTAAT
apxIIIA Forward: ACGGGATCCTGGTCAAGCATGTTAG 52°C 3114
Reverse: ATGCGTCGACTGCTCTAGCTAGGTTACC
apxIVA Forward: GCCGAATTCCGCGCCTATATCTGG 54°C 2553
Reverse: ATGCGTCGACCCCTTCGAATTGTTTC
Omp Forward: GGAATTCACGCCTAAGGTTGATAT 53°C 984
Reverse: GGTCGACCTTTATCTTCTTTTGTTG
Apfa Forward: GGGCGAATTCATGCAAAAACTAAGT 53°C 444
Reverse: TATGGTCGACTGATGCGCAGAAAT
Note:
BamH I site: Underlined; EcoR I site: Italic; SaI I site: Bold; PCRs were run for 30 cycles.
Table 2 The antigens described and vaccine components of immunized mice
Groups vaccine components
antigens described protein content
Control total protein concentration was 100 μg/ml rApxI, rApxII, rApxIII and rOMP
Group I total protein concentration was 150 μg/ml rApxI, rApxII, rApxIII, rApxIV, rOMP and rApfa
Group II 10
9 colony forming units (CFU)/ml inactivated APP1 whole cell
Group III phosphate-buffered saline (PBS) PBS
Note:
1. APP1 inactivated with 0.3% formaldehyde solution.
2. The vaccine components of all the immunized groups as well as the control group were emulsified with an equal volume of mineral oil adjuvant (Sigma-
Aldrich).
Effect of challenge with APP1 and APP2 on vaccinated mice
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animals in each group were subdivided again into two
equal subgroups within each group. The mice in one
subgroup of each group were challenged intranasally
with 5 × 10
9 colony forming units (CFU) of APP1, and
the mice in the other subgroups were challenged with
APP2 (5 × 10
10 CFU). The LD50 was calculated as
described previously [28]. Animals were sacrificed on
the sixth day after challenge.
Histopathology and indirect immunofluorescence (IIF) test
Lung samples were separated into two parts. One part
was fixed by formalin, followed by hematoxylin and
eosin (HE) staining for the observation of histological
changes. Briefly, the lung of each mouse was fixed in
10% formalin, embedded in paraffin and cut into 5-6
μm sections. All sections were heated at 56°C for 25
min, deparaffinized in xylene, rehydrated with graded
alcohols, and then stained with HE for histological
observation using light microscopy (Olympus, Tokyo,
Japan).
The other part of each lung was cut into sections
using a freezing microtome for the detection of the dis-
tribution of APP in lung tissue using the IIF method
[29]. Briefly, lung samples were embedded in a Tissue-
Tek OCT compound (Miles, Inc., Elkhart, IN) and fro-
z e ni nl i q u i dn i t r o g e n .F r o z e ns e c t i o n s( 4μm) were
mounted on slides coated with poly-L-lysine and fixed
in pre-cooled acetone for 5 min. Sections were then
covered with 20 μl rabbit antiserum against APP1 or
APP2 (1:50 dilution) and incubated at 37°C for 1 h.
After washing in PBS, the sections were covered with 20
μl FITC-labeled goat anti-rabbit IgG (Sigma-Aldrich)
(1:100 dilution) and incubated at 37°C for 1 h. Immuno-
fluorescence images were observed with an Olympus
A×70 fluorescence microscope (Olympus, Tokyo, Japan).
Results
Purification and concentration of the recombinant
proteins
The purity of the expressed recombinant rApxI, rApxII,
rApxIII, rApxIV and rApfa as well as rOMP protein was
approximately 90%-95% after analysis by SDS-PAGE and
thin-layer scan, and the concentrations of rApxI, rApxII,
rApxIII, rApxIV, rApfa and rOMP were 150 μg/ml, 115
μg/ml, 140 μg/ml, 95 μg/ml, 80 μg/ml and 200 μg/ml,
respectively.
Detection of serum antibodies
The serum antibodies to rApxI, rApxII, rApxIII, rOMP
and rApfa in various groups were examined and the
findings are summarized in Fig. 1.
Two weeks after the second immunization, antibodies
against rApxI and rOMP in the mice in group I were
significantly higher (P < 0.01) than those in the other
three groups. Antibodies against rApxII and rApxIII
were also higher in the mice in Group I than in the
other three groups (P < 0.05). All antibody levels of the
mice in Group I (against rApxI, rApxII, rApxIII and
rOMP) were significantly higher (P < 0.01) than those in
the other three groups one week after the third immuni-
zation (Table 3).
Antibodies against rApxI, rApxII, rApxIII and rApfa
were significantly higher in the mice in Group II than in
those in Group III and in the control group 2 weeks
after the second immunization (P < 0.05). The rOMP
antibody level of the mice in Group II was the same as
that of Group III and these levels were significantly
higher than that in the control group (P <0 . 0 1 ) .A n t i -
body levels against rApxI, rApxII, rApxIII and rApfa in
the mice in Group III were slightly higher than those in
the control group but were not significantly different
(P > 0.05).
Mortality and histopathology
The challenge doses of APP1 Shope 4074 and APP2
S1536 were 5×10
9 cfu and 5×10
10 cfu respectively.
Within 24 h after challenge with APP1 and 36 h after
challenge with APP2, all control mice died. The survival
rate of Group I was higher than that of Groups II and
III (P< 0.05) and the control group (P< 0.01). The
results are summarized in Table 2. Bleeding from the
mouth and nose was apparent in all dead mice. The
lungs of the dead mice challenged with APP1 (Fig. 2a)
and APP2 (Fig. 2e) showed severe lung lesions. Conges-
tion, hemorrhage, necrosis and parenchyma consolida-
tion were observed in the lungs, and extensive serous
and fibrinous exudates had accumulated together with a
substantial infiltration of inflammatory cells. All the
other surviving mice were euthanized 5 days post chal-
lenge with APP1 or APP2. The mice in Group I chal-
lenged with APP1 (Fig. 2b) or APP2 (Fig. 2f) had less
severe lung lesions than those in Groups II and III
(Fig. 2c, 2d, 2g, 2h), with less hemorrhage and necrosis.
The mice in Groups II and III showed moderate lung
lesions, with pulmonary congestion, hemorrhage, serous
and fibrinous exudation in some areas, inflammatory
cell infiltration, as well as partial rupture of alveolar
structures, and lysis.
IIF detection
The results of IIF detection are shown in Table 4. In
Group I, there were only weak and scattered fluorescent
dots observed in individual alveoli and alveolar septa of
the surviving mice. In contrast, in those in groups and
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Page 4 of 8Figure 1 Antibody levels against rApxI, rApxII, rApxIII, rOMP and rApfa. 1a: ApxI, 1b:ApxII, 1c:ApxIII, 1d: Apfa, 1e: OMP
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stronger than in Group I. However, the strongest fluor-
escence was observed in most alveoli and alveolar septa
of the dead mice in the control group as well as those
in Groups I-III.
Discussion
This study showed that a recombinant subunit vaccine
consisting of rApxI, rApxII, rApxIII and rOMP can pro-
tect mice effectively against challenge with APP1 and
APP2. This demonstrates that the recombinant subunit
vaccine can induce favorable cross-protection. Com-
pared with this, the cross-protection efficacy of the inac-
tivated vaccine (Group III) was significantly lower than
that in Group I. This may be due to the lower antibody
level against Apx toxin in group III, which indicates the
importance of Apx toxin for cross-protection [2,3,6].
The results showed that the antibodies against rApxI,
rApxII, and rApxIII in Group I were higher than those
in the other groups, which could have contributed to
the better protection of this group. Furthermore, with
increasing in the time since immunization, the antibody
levels also increased, especially the antibodies against
rApxI and rOMP; there was a large rise between the
second and third immunization. Because ApxIV toxin
has been shown to be produced only in vivo, it can not
be extracted from cultures to design diagnostic tools
from a culture of APP to use as the diagnostic antigen
in iELISA. Therefore, we did not detect the antibody
titer of rApxIV. However, the positive effect of rApxIV
o nt h ei m m u n er e s p o n s ei sr e f l e c t e di nt h er e s u l t so f
the challenge experiment [30].
During these experiments, we showed that the protec-
tive efficacy of the vaccine did not improve against
APP1 and APP2 after rApfa was added to the vaccine
containing rApxI, rApxII, rApxIII and rOMP. Instead
the protective efficacy was decreased, suggesting that
the protective efficacy was lower than before. Suggesting
that rApfa may just have a negative effect when com-
bined with other factors in Group II, the antibody titers
against rApxI, rApxII, rApxIII and rOMP decreased fol-
lowing the addition of rApfa. It is interesting that, the
antibody titers against rApxI and rApxIII declined with
an increase in the time since immunization. We propose
that the rApfa may impair immunity or rApfa antibody
counteracted the other antibodies to rApxI, rApxII, rAp-
xIII and rOMP in Group II. However, we determined
the antibody titer of rApfa, and the result showed that it
rose slowly along with the increase in time since immu-
nization. These results are similar to those of a previous
study, in which the protective efficacy of a subunit vac-
cine containing three antigens (PalA, ApxI and ApxII)
was considerably lower than that containing two anti-
gens (ApxI and ApxII). This could indicate that PalA
antibody counteracted ApxI and ApxII antibodies, and
thus interfered with immunity [9].
In summary, rApfa interfere with the other antibodies
against toxins of APP. Consequently, the fluorescence
dots in group II were more dense and stronger than in
group I and the mice in group II challenged with APP1
or APP2 had more severe lung lesions than those in
group I. In addition, the survival rate of Group II was
lower than that of Group I. It indicated that there was
no positive correlation between the quantity of multi-
component recombinant vaccines antigen components
and immune protection, the optimization of the antigen
components was the key to a better immune protection.
Finally, which component of rApfa may interfere with
immunity when mixed with other antigens should be
studied further. After all, the mouse is only a model for
this study.
Conclusion
The result of this study indicates that the multicompo-
nent recombinant subunit vaccine composed of rApxI,
rApxII, rApxIII and rOMP can provide effective cross-
protection against challenge with APP1 and APP2.
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Table 3
Groups Challenge with APP1 Challenge with APP2
Survival Lung lesion Survival Lung lesion
Control 0/10 Severe
b 0/10 Severe
b
Group I 9/10 Slight
a Severe
b 9/10 Slight
a Severe
b
Group II 5/10 Moderate
a Severe
b 6/10 Moderate
a Severe
b
Group III 6/10 Moderate
a Severe
b 7/10 Moderate
a Severe
b
a Surviving mice;
b Dead mice
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Page 6 of 8Figure 2 Histopathology of lungs from mice in various groups after challenge with APP1 or APP2 (HE staining 200 × magnification).
2a: Control group challenged with APP1; 2b: Group I challenged with APP1; 2c: Group II challenged with APP1; 2d: Group III challenged with
APP1; 2e: Control group challenged with APP2; 2f: Group I challenged with APP 2; 2g: Group II challenged with APP2; 2h: Group III challenged
with APP2.
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Table 4 Detection of APP1 or APP2 in the lungs of mice
by indirect immunofluorescence (IIF)
Groups Detection of APP
Challenge with APP1 Challenge with APP2
Control ++
b ++
b
Group I ±
a ++
b ±
a ++
b
Group II +
a ++
b +
a ++
b
Group III +
a ++
b +
a ++
b
Fluorescence intensity: Weak: ±; Medium: +; Strong: ++ [29]
a Surviving mice;
b Dead mice
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